Abstract:Abstract Background Introduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting Stents (DES) maintained its superiority over BMS in every aspect from restenosis rate to late lumen loss. The reason behind the magnanimous position of the DES in the stent market is the degree of improvement with which it evolves. New and better stents come into the market every year, surpassing their predecessors by many folds. Literature review This review paper discusses the journey of DES with supporting clinical trials in detail. In the first generation, there were stainless-steel stents with thicker coatings. Although they had superior results compared to BMS, there was still room for improvement. Afterward came the second-generation stents, which had superior metal platforms with thinner struts and thin coatings. The drugs were also changed from Paclitaxel and Sirolimus to Zotrolimus and Everolimus. These stents performed best; however, there was an issue of permanent coating, which remained intact over the stent surface after complete drug elution and started to cause issues in longer-term studies. Hence, an improved version of DES was introduced to these permanent coatings called the third generation of drug eluting stents, which initially utilized biodegradable polymer and ultimately moved towards polymer free drug coatings. This generation has introduced a unique amalgam of technologies to achieve its polymer free coatings; however, researchers have numerous prospects of growth in this field. This review paper highlights the major coups of stent technology evolution from BMS to DES, from thick polymeric coatings to thin coatings and from durable polymers to polymer free DES. Conclusion In conclusion, though the medical industry promptly accepted BMS as the best treatment option for cardiovascular diseases; however, DES has provided even better results than BMS. In DES, the first and second generation has ruled the technology for many years and are still on the shelves. Still, the issues aroused due to durable polymer shifted the attention towards biodegradable drug eluting stents, the third generation growing rapidly. But the scientific community has not restricted themselves and is investigating bioresorbable stents that completely eliminate the polymer intervention in drug eluting stent technology.

A Synopsis of Stent Graft Technology Development

Bio-resorbable polymer stents: a review of material progress and prospects

Nanotechnology in development of next generation of stent and related medical devices: Current and future aspects

A Survey of Coronary Stents Development

Current Status and Prospect of Novel Coronary Stent

Coronary Stent Materials and Coatings: A Technology and Performance Update

Advances in the development of biodegradable coronary stents: A translational perspective

Biodegradable Stents for Coronary Artery Disease Treatment: Recent Advances and Future Perspectives

Recent Advances in Cardiovascular Stent for Treatment of In-Stent Restenosis: Mechanisms and Strategies

The Road to the Ideal Stent: A Review of Stent Design Optimisation Methods, Findings, and Opportunities

Hemodynamics of Coronary Stent

Current status and future direction of metallic and polymeric materials for advanced vascular stents

The Use of Bioactive Polymers for Intervention and Tissue Engineering: The New Frontier for Cardiovascular Therapy

Coronary balloon angioplasty, stents, and scaffolds

Biomedical Material for Stent Application: Current Status and Future Challenges

Drug-Eluting Stents: Technical and Clinical Progress

Evolutionary perspective of drug eluting stents: from thick polymer to polymer free approach

Current status and prospect of drug-eluting stents

The Development of Design and Manufacture Techniques for Bioresorbable Coronary Artery Stents

An overview of polymer-based-bioresorbable drug-eluting stents

Structural Design of Vascular Stents: A Review